← Back to Clinical Trials
Recruiting NCT05683093

NCT05683093 Cardiovascular Longitudinal ALSPAC Research Investigations Following Hypertensive Pregnancy in Young Adulthood

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05683093
Status Recruiting
Phase
Sponsor University of Oxford
Condition Young Adult
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2022-11-17
Primary Completion 2026-03-01

Eligibility & Interventions

Sex All sexes
Min Age 30 Years
Max Age 40 Years
Study Type OBSERVATIONAL
Interventions
History of being born to hypertensive or normal pregnancy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 2022-11-17 with a primary completion date of 2026-03-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to understand more about why young people who were born to a hypertensive pregnancy may have increased risk of high blood pressure and are often at increased risk of heart and blood vessel disease later in life.

Eligibility Criteria

Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study * Male or female, aged 30 to 40 years at time of enrolment * Participant previously took part in the ALSPAC study * Able (in the investigator's opinion) and willing to comply with all study requirements * Adequate understanding of verbal and written English Exclusion Criteria: * Pregnant or lactating when they are due to attend for study visit 1 * Less than six months postpartum * Planning to donate blood within two weeks prior to study visit 1 * Any significant disease or disorder which, in the opinion of the investigator, might influence the participant's ability to participate in the study * Evidence of congenital heart disease or significant chronic disease relevant to cardiovascular or metabolic status For exclusion of MRI component only: * Unsuitable for MRI based on participant screening; the participant may still be included in other parts of the study

Contact & Investigator

Central Contact

Katie Suriano

✉ clarity@cardiov.ox.ac.uk

📞 01865 226845

Principal Investigator

Adam J Lewandowski

PRINCIPAL INVESTIGATOR

Cardiovascular Clinical Research Facility

Frequently Asked Questions

Who can join the NCT05683093 clinical trial?

This trial is open to participants of all sexes, aged 30 Years or older, up to 40 Years, studying Young Adult. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05683093 currently recruiting?

Yes, NCT05683093 is actively recruiting participants. Contact the research team at clarity@cardiov.ox.ac.uk for enrollment information.

Where is the NCT05683093 trial being conducted?

This trial is being conducted at Oxford, United Kingdom.

Who is sponsoring the NCT05683093 clinical trial?

NCT05683093 is sponsored by University of Oxford. The principal investigator is Adam J Lewandowski at Cardiovascular Clinical Research Facility. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology